PMP22 Gene CMT1A Genetic Test
At DNA Labs UAE, we offer the PMP22 Gene CMT1A Genetic Test at a cost of AED 4400.0.
Test Details
The PMP22 gene is associated with the development of Charcot-Marie-Tooth disease type 1A (CMT1A), a hereditary neuropathy that affects the peripheral nerves. This gene is located on chromosome 17 and encodes a protein called peripheral myelin protein 22 (PMP22), which is crucial for the formation and maintenance of myelin in the peripheral nervous system.
Our PMP22 Gene CMT1A Genetic Test utilizes NGS (next-generation sequencing) technology, allowing for rapid and accurate sequencing of DNA. By analyzing the PMP22 gene using NGS, we can identify any mutations or variations that may be associated with CMT1A.
This test serves as a diagnostic tool to confirm a suspected diagnosis of CMT1A or to identify individuals who may be at risk for developing the condition. It is typically performed on a blood sample or a saliva sample.
The results of this test are crucial for healthcare providers in determining the best course of treatment and management for the patient. However, it is important to note that genetic testing for CMT1A is not always necessary or appropriate, and should be discussed with a healthcare provider or genetic counselor.
Furthermore, it is important to consider the implications of testing on family members, as CMT1A is an inherited condition. A genetic counseling session is recommended to draw a pedigree chart of family members affected by PMP22 Gene CMT1A.
Test Components and Price
- Test Name: PMP22 Gene CMT1A Genetic Test
- Components: NGS Technology
- Price: AED 4400.0
- Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
- Report Delivery: 3 to 4 Weeks
- Test Type: Neurological Disorders
- Doctor: Neurologist
- Test Department: Genetics
Pre Test Information
Prior to the PMP22 Gene CMT1A NGS Genetic DNA Test, it is important to provide the clinical history of the patient. Additionally, a genetic counseling session is recommended to draw a pedigree chart of family members affected by PMP22 Gene CMT1A.
Genetic counseling can help assess the risk of CMT1A in family members and provide appropriate guidance and support.
Conclusion
The PMP22 Gene CMT1A Genetic Test offered by DNA Labs UAE is a valuable diagnostic tool for confirming a suspected diagnosis of CMT1A or identifying individuals at risk for developing the condition. By utilizing NGS technology, we can accurately analyze the PMP22 gene for any mutations or variations. It is important to discuss the necessity of testing with a healthcare provider or genetic counselor, as well as consider the implications for family members.
| Test Name | PMP22 Gene CMT1A Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card o |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Neurological Disorders |
| Doctor | Neurologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for PMP22 Gene CMT1A NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with PMP22 Gene CMT1A |
| Test Details |
The PMP22 gene is associated with the development of Charcot-Marie-Tooth disease type 1A (CMT1A), which is a hereditary neuropathy that affects the peripheral nerves. The PMP22 gene is located on chromosome 17 and encodes a protein called peripheral myelin protein 22 (PMP22), which is important for the formation and maintenance of myelin in the peripheral nervous system. NGS (next-generation sequencing) is a genetic testing method that allows for the rapid and accurate sequencing of DNA. The PMP22 gene can be analyzed using NGS technology to identify mutations or variations that may be associated with CMT1A. The PMP22 gene test is a diagnostic tool used to confirm a suspected diagnosis of CMT1A or to identify individuals who may be at risk for developing the condition. The test is typically performed on a blood sample or a saliva sample, and the results can help healthcare providers determine the best course of treatment and management for the patient. It is important to note that genetic testing for CMT1A is not always necessary or appropriate, and should be discussed with a healthcare provider or genetic counselor. Testing may also have implications for family members, as CMT1A is an inherited condition. |
